Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company pioneering precision oncology through its proprietary AP3 proteomics platform. This page provides investors and researchers with essential updates on ACRV's drug development programs, clinical trial progress, and technological advancements.
Access real-time press releases and curated analysis covering regulatory milestones, partnership announcements, and scientific presentations. Our repository includes updates on lead candidates ACR-368 (CHK1/CHK2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor), alongside developments in companion diagnostics and proteomics innovation.
Key content categories include clinical trial updates, platform enhancements, executive leadership announcements, and peer-reviewed research highlights. All materials are vetted for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to ACRV's latest developments in targeted cancer therapies. Check regularly for authoritative updates on one of precision oncology's most innovative platforms.
Acrivon Therapeutics (Nasdaq: ACRV) announced a virtual investor event on September 14, 2024, to review positive Phase 2 clinical data of ACR-368 presented at ESMO and pipeline progress. The event will highlight:
1. Updated ACR-368 clinical data in endometrial cancer from the ongoing registrational intent Phase 2b study
2. Updates on lead assets ACR-368, ACR-2316, and the AP3 platform
3. Previous data showed a 50% confirmed response rate across ovarian and endometrial cancer patients
4. Enrollment for endometrial cancer patients is progressing ahead of schedule
5. The study represents the first potential approval opportunity for ACR-368
The ESMO poster presentation details and webcast information are provided in the announcement.
Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2024 financial results and business highlights. Key points include:
- Planned webcast in September 2024 during ESMO conference to update on clinical programs and AP3 platform progress
- Initial positive clinical data for ACR-368 showed 50% overall response rate in gynecological cancers
- On track to initiate Phase 1 study for ACR-2316 in Q4 2024
- Executed $130 million private placement financing
- Q2 2024 net loss of $18.8 million, compared to $13.9 million in Q2 2023
- Cash position of $220.4 million, expected to fund operations into second half of 2026
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
Acrivon Therapeutics reported its first quarter 2024 financial results and business highlights on May 14, 2024. The company, which leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines, made significant strides in its clinical and preclinical pipeline.
Key achievements include the validation of the AP3 platform's ACR-368 OncoSignature assay, demonstrating a 50% overall confirmed response rate in patients with ovarian and endometrial cancer. The company has also accelerated the IND timeline for ACR-2316, a new WEE1/PKMYT1 inhibitor, with clinical trials expected to begin in Q4 2024. Financially, Acrivon reported a net loss of $16.5 million for Q1 2024, compared to $12.8 million in Q1 2023. The company raised $130 million in a private placement, extending its cash runway into H2 2026.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
